Omega-3 Fish Oil — Essential polyunsaturated fatty acid (n-3 PUFA)
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) incorporate into phospholipid membranes and compete with arachidonic acid (AA) for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production toward less pro-inflammatory resolvins and protectins. EPA reduces triglycerides via PPAR-α activation and VLDL secretion inhibition. DHA is critical for neuronal membrane fluidity and photoreceptor function. High-dose EPA reduces MACE (REDUCE-IT, n=8,179; STRENGTH). VITAL trial (n=25,871) showed 28% reduction in fatal MI.
نظرة عامة
هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.
فئة المركّب
Essential polyunsaturated fatty acid (n-3 PUFA)
آلية العمل
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) incorporate into phospholipid membranes and compete with arachidonic acid (AA) for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production toward less pro-inflammatory resolvins and protectins. EPA reduces triglycerides via PPAR-α activation and VLDL secretion inhibition. DHA is critical for neuronal membrane fluidity and photoreceptor function. High-dose EPA reduces MACE (REDUCE-IT, n=8,179; STRENGTH). VITAL trial (n=25,871) showed 28% reduction in fatal MI.
الوضع التنظيمي
OTC at standard doses. Prescription-grade high-purity forms (Vascepa/Icosapentaenoic acid, Lovaza) FDA-approved for severe hypertriglyceridemia and CV risk.
مستوى الأدلة
High — multiple large RCTs. FDA-approved prescriptions at 4 g/day (Vascepa, Lovaza). AHA position statement supports use for hypertriglyceridemia and cardiovascular risk.